RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+10.81%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$4.15B
AUM Growth
+$4.15B
(+17%)
Cap. Flow
+$521M
Cap. Flow
% of AUM
12.54%
Top 10 Holdings %
Top 10 Hldgs %
45.29%
Holding
99
New
22
Increased
37
Reduced
6
Closed
9
Top Buys
| 1 |
Immunovant
IMVT
|
$63.1M |
| 2 |
Illumina
ILMN
|
$54.1M |
| 3 |
Guardant Health
GH
|
$52.5M |
| 4 |
Athira Pharma
ATHA
|
$45.4M |
| 5 |
Cytokinetics
CYTK
|
$40.7M |
Top Sells
| 1 |
Wave Life Sciences
WVE
|
$24.9M |
| 2 |
Q32 Bio
QTTB
|
$19.6M |
| 3 |
STAAR Surgical
STAA
|
$19M |
| 4 |
NeoGenomics
NEO
|
$13.8M |
| 5 |
Repare Therapeutics
RPTX
|
$6.98M |
Sector Composition
| 1 | Healthcare | 92.6% |
| 2 | Materials | 0.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rocket Pharmaceuticals
RCKT
$354M
| $384M | 9.25% | 16,812,491 | – | – |
|
|
2
Immunovant
IMVT
$2.56B
| $264M | 6.36% | 7,510,412 +1,793,230 | +31% | +$63.1M |
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $245M | 5.9% | 1,681,645 | – | – |
|
4
PTC Therapeutics
PTCT
$3.92B
| $187M | 4.49% | 3,993,286 +30,166 | +0.8% | +$1.41M |
|
|
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $182M | 4.38% | 1,096,005 +8,279 | +0.8% | +$1.37M |
|
|
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $130M | 3.13% | 7,227,413 +74,495 | +1% | +$1.34M |
|
|
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $128M | 3.08% | 936,931 | – | – |
|
8
Natera
NTRA
$23.1B
| $124M | 2.98% | 1,710,769 +181,641 | +12% | +$13.1M |
|
9
Axsome Therapeutics
AXSM
$6.05B
| $119M | 2.87% | 1,670,938 +12,622 | +0.8% | +$899K |
|
10
Stoke Therapeutics
STOK
$1.08B
| $119M | 2.86% | 3,544,248 | – | – |
|
11
Avidity Biosciences
RNA
$5.99B
| $110M | 2.65% | 3,995,000 | – | – |
|
12
Masimo
MASI
$7.59B
| $106M | 2.56% | 450,390 +61,614 | +16% | +$14.5M |
|
|
CERN
13
DELISTED
Cerner Corp
CERN
| $101M | 2.42% | 1,392,049 +209,640 | +18% | +$15.2M |
|
|
AXNX
14
DELISTED
Axonics, Inc. Common Stock
AXNX
| $96.2M | 2.32% | 1,883,864 +607 | +0% | +$31K |
|
15
Baxter International
BAX
$12.7B
| $86.6M | 2.09% | 1,077,268 +107,898 | +11% | +$8.68M |
|
16
10x Genomics
TXG
$1.74B
| $82.4M | 1.98% | 660,933 +24,841 | +4% | +$3.1M |
|
17
Adverum Biotechnologies
ADVM
$64.6M
| $74.5M | 1.79% | 7,234,764 +444,737 | +7% | +$4.58M |
|
18
Vericel Corp
VCEL
$1.83B
| $71.4M | 1.72% | 3,850,851 +504 | +0% | +$9.34K |
|
19
Tandem Diabetes Care
TNDM
$845M
| $68.5M | 1.65% | 603,481 +4,558 | +0.8% | +$517K |
|
20
Protagonist Therapeutics
PTGX
$3.67B
| $66.6M | 1.6% | 3,408,961 +25,753 | +0.8% | +$503K |
|
21
Relmada Therapeutics
RLMD
$37.2M
| $56.9M | 1.37% | 1,511,337 +30,485 | +2% | +$1.15M |
|
|
22
Illumina
ILMN
$15.8B
| $54.1M | 1.3% | +175,000 | New | +$54.1M |
|
|
23
Guardant Health
GH
$8.41B
| $52.5M | 1.26% | +469,498 | New | +$52.5M |
|
|
AGEN
24
Agenus
AGEN
$133M
| $51.5M | 1.24% | 12,864,677 | – | – |
|
|
TBIO
25
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $51M | 1.23% | 3,745,286 +28,292 | +0.8% | +$385K |
|